Clinical Trials
521
Trial Phases
5 Phases
Drug Approvals
4
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (407 trials with phase data)• Click on a phase to view related trials
A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants
- Conditions
- Mid Face Volume Deficit
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 171
- Registration Number
- NCT05452070
- Locations
- 🇨🇦
YVR Aesthetics Training & Study Centre /ID# 239809, Vancouver, British Columbia, Canada
🇨🇦Humphrey & Beleznay Cosmetic Dermatology /ID# 239805, Vancouver, British Columbia, Canada
🇨🇦Pacific Derm /ID# 240785, Vancouver, British Columbia, Canada
Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Allergan
- Registration Number
- NCT05393089
- Locations
- 🇺🇸
Trinity Research Group /ID# 243541, Dothan, Alabama, United States
🇺🇸Arizona Eye Center /ID# 243897, Chandler, Arizona, United States
🇺🇸Global Research Management /ID# 243544, Glendale, California, United States
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 309
- Registration Number
- NCT05248880
- Locations
- 🇺🇸
Clear Dermatology & Aesthetics Center /ID# 238990, Scottsdale, Arizona, United States
🇺🇸Steve Yoelin MD Medical Assoc. Inc /ID# 243197, Newport Beach, California, United States
🇺🇸Marcus Facial Plastic Surgery /ID# 241703, Redondo Beach, California, United States
A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 124
- Registration Number
- NCT05152576
- Locations
- 🇺🇸
Steve Yoelin MD Medical Associate Inc /ID# 239771, Newport Beach, California, United States
🇺🇸Duplicate_Austin Institute for Clinical Research /ID# 239783, Pflugerville, Texas, United States
🇺🇸The Eye Research Foundation /ID# 241512, Newport Beach, California, United States
HArmonyCa Injectable Gel for Mid Face Soft Tissue Augmentation
- Conditions
- Soft Tissue Augmentation
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 140
- Registration Number
- NCT05119777
- Locations
- 🇫🇷
Eurofins Dermscan Pharmascan /ID# 240921, Aix-en-Provence, France
🇫🇷Eurofins Pharmascan /ID# 240920, Lyon, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 102
- Next
News
MannKind Appoints Dr. Ajay Ahuja as Chief Medical Officer to Advance Inhaled Therapeutics Pipeline
MannKind Corporation has appointed Dr. Ajay Ahuja as Chief Medical Officer, bringing over two decades of biopharmaceutical leadership experience to advance the company's inhaled therapeutics pipeline.
Amneal Pharmaceuticals Receives FDA Approval for Generic Bimatoprost Eye Drops to Treat Glaucoma
Amneal Pharmaceuticals received FDA approval for its generic version of bimatoprost ophthalmic solution 0.01%, a prostaglandin analog used to reduce elevated intraocular pressure in glaucoma patients.
Uniquity Bio Appoints Will Kane as CEO to Lead Anti-TSLP Therapy Through Phase III Development
Uniquity Bio has appointed Will Kane as President and CEO to advance solrikitug, a monoclonal antibody targeting TSLP, through completion of three Phase II trials and preparation for Phase III development.
Incyte Names Bill Meury as New CEO, Replacing 11-Year Veteran Hervé Hoppenot
Incyte has appointed Bill Meury as its new CEO, effective immediately, replacing Hervé Hoppenot who led the cancer and blood disease drugmaker for 11 years.
Amneal Secures FDA Approval for Generic Prednisolone Acetate Eye Drops, Targeting $201 Million Market
Amneal Pharmaceuticals received FDA approval for prednisolone acetate ophthalmic suspension 1%, a generic version of Allergan's Pred Forte for treating steroid-responsive ocular inflammation.
CollPlant Expands STEMCELL Technologies Partnership to Include Clinical and Commercial Applications of Plant-Derived Collagen
CollPlant Biotechnologies has expanded its collaboration with STEMCELL Technologies to include clinical development and commercial-scale manufacturing of its plant-derived recombinant human collagen (rhCollagen).
CollPlant Advances Regenerative Breast Implant Technology with Promising Preclinical Results
CollPlant reported encouraging preclinical results for its regenerative breast implants, which demonstrated vascularization, tissue ingrowth, and biodegradation while maintaining structural integrity six months post-implantation.
Perfluorohexyloctane Shows Unprecedented Rapid Relief for Dry Eye Disease in Phase 4 Study
A phase 4 multicenter study demonstrated that perfluorohexyloctane (MIEBO) provides significant dry eye symptom relief within just 5 minutes of application, showing nearly 50% improvement that continued to increase at subsequent timepoints.
Galapagos CEO Paul Stoffels to Step Down as Company Splits into Two Entities
Paul Stoffels will retire as Galapagos CEO within 12 months after three years at the helm, during which he transformed the company's focus to cell therapy and oncology through strategic acquisitions.
SpyGlass Pharma Appoints Veteran Pharmaceutical Executive as Chief R&D Officer to Advance Intraocular Drug Delivery Platform
• SpyGlass Pharma has appointed Chetan Pujara, Ph.D., as Chief Research & Development Officer to lead the company's proprietary intraocular drug delivery platform into Phase 3 trials. • Dr. Pujara brings over 20 years of leadership experience in pharmaceutical development and has contributed to market-leading products including Ozurdex®, Durysta™, and other ophthalmic therapies. • The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver three years of sustained medication release for glaucoma patients, with potential applications in additional ophthalmic conditions.